No

Cholinergic Agonist; Ophthalmic Agent, Antiglaucoma; Ophthalmic Agent, Miotic

Management of chronic simple glaucoma, chronic and acute angle-closure glaucoma; strabismus

C

Although there are no reports of use in pregnancy, demecarium is an ophthalmic medication and transplacental passage in significant amounts would not be expected

Hypersensitivity to demecarium or any component, acute inflammatory disease of anterior chamber; pregnancy

1% to 10%: Ocular: Stinging, burning eyes, myopia, visual blurring

<1%: Bradycardia, hypotension, flushing, nausea, vomiting, diarrhea, muscle weakness, retinal detachment, miosis, twitching eyelids, watering eyes, dyspnea, diaphoresis

Antidote: Atropine sulfate: Adults: 0.4-0.6 mg (1/150-1/100 grain) or more parenterally

No data reported

Do not freeze; protect from heat

Cholinesterase inhibitor (anticholinesterase) which causes acetylcholine to accumulate at cholinergic receptor sites and produces effects equivalent to excessive stimulation of cholinergic receptors. Demecarium mainly acts by inhibiting true (erythrocyte) cholinesterase and causes a reduction in intraocular pressure due to facilitation of outflow of aqueous humor; the reduction is likely to be particularly marked in eyes in which the pressure is elevated.

Children/Adults: Ophthalmic:

Strabismus:

Diagnosis: Instill 1 drop daily for 2 weeks, then 1 drop every 2 days for 2-3 weeks. If eyes become straighter, an accommodative factor is demonstrated.

Therapy: Instill not more than 1 drop at a time in both eyes every day for 2-3 weeks. Then reduce dosage to 1 drop every other day for 3-4 weeks and re-evaluate. Continue at 1 drop every 2 days to 1 drop twice a week and evaluate the patient's condition every 4-12 weeks. If improvement continues, reduce dose to 1 drop once a week and eventually off of medication. Discontinue therapy after 4 months if control of the condition still requires 1 drop every 2 days.

None reported

None reported

No information available to require special precautions

No effects or complications reported

For the eye; do not touch dropper to eye; transient burning or stinging may occur; do not use more often than directed

Finger pressure should be applied to lacrimal sac for 1-2 minutes after instillation to decrease risk of absorption and systemic reactions; patient must be under supervision and tonometric examinations performed every 3-4 hours following initiation of therapy

Solution, ophthalmic, as bromide: 0.125% (5 mL); 0.25% (5 mL)